Topadur Appoints Matthias Schäfer as Chief Executive Officer to Lead Next Phase of Company Growth

EQS-News: Topadur Pharma AG / Key word(s): Personnel Topadur Appoints Matthias Schäfer as Chief Executive Officer to Lead Next Phase of Company Growth 17.12.2025 / 09:30 CET/CEST The issuer is solely responsible for the content of this announcement. 17 December 2025

Topadur Appoints Matthias Schäfer as Chief Executive Officer to Lead Next Phase of Company Growth

• Founder and President of the Board Dr. Reto Naef assumes the role of Senior Scientific Advisor, continuing to support the company’s scientific direction
• Company enters next phase of clinical advancement with programs progressing toward strategic milestones

Zurich, Switzerland - Topadur Pharma AG, a clinical-stage biotechnology company developing innovative therapies for vascular regeneration, today announced the appointment of PD Dr. Matthias Schäfer as Chief Executive Officer.

Dr. Schäfer joined Topadur in 2024 as Chief Innovation Officer and Deputy CEO and now assumes executive leadership as the company advances its pipeline into the next stages of clinical development toward commercialization.

Founder Dr. Reto Naef remains on the leadership team as Senior Scientific Advisor and continues to guide the company’s strategy as President of the Board, ensuring continuity in Topadur’s long-term growth.

Matthias Schäfer brings more than 20 years of experience across the life sciences and healthcare sectors. He has directed research and clinical development programs, driven global portfolio expansion, and established strategic partnerships across diverse therapeutic areas. Dr. Schäfer has held senior leadership roles including at Geistlich Pharma AG and pfm medical GmbH, where he translated scientific innovation into sustainable commercial growth and strengthened global market presence. He received a PhD in Biology from the University of Würzburg and completed his habilitation at ETH Zurich.